5 European biotech startups to watch – according to VC investor from b2venture

2024 was a year of contrasts for the German biotech scene : record investments of 1.9 billion euros, including 898 million euros in venture capital financing, but at the same time declines in sales (minus eight percent) and employment (minus five percent).

A look at the EY Biotech Report 2025 shows that the industry is struggling with structural problems such as a lack of scale, slow approvals, and capital fragmentation – while at the same time having enormous scientific potential.

New momentum is evident, especially in the early stages: the number of new companies rose from 24 to 39 last year, seed financing tripled, and more and more startups are emerging at the interface of biology and technology.

One investor who invests in precisely this area is Marisa Krummrich, a VC investor at the early-stage fund b2venture . She is closely monitoring the next generation of biotech teams that are developing new solutions for research, diagnostics, and clinical trials using software, automation, and AI.